FDA revokes emergency use of chloroquine and hydroxychloroquine for COVID-19

Read: The FDA says determining chloroquine and hydroxychloroquine may not be effective in treating COVID-19today, the U.SFood and Drug Administration (FDA) issued a statement withdrawing the Emergency Use Authorization (EUA) for the treatment of COVID-19 hospitalizationsOn March 28, the FDA issued the emergency authorizationIn its latest statement, thesaid that determining chloroquine and hydroxychloroquine may not be effective in treating COVID-19this based on the latest results of a large randomized clinical trial for inpatients (similar to those authorized to use chloroquine and hydroxychloroquine)The results showed that hydroxychloroquine had no benefit in mortality or accelerated rehabilitationThe results are consistent with other new data: chloroquine and hydroxychloroquine administration are unlikely to kill or suppress the virus that causes COVID-19All available scientific evidence suggests a lack of benefits, given the ongoing severe heart events and other potentially serious side effects, the potential benefits of chloroquine and hydroxychloroquine do not exceed the known and potential risks of authorized use"While other clinical trials continue to assess the potential benefits of these drugs in the treatment or prevention of COVID-19, we have determined that emergency use authorization is no longer appropriate," said DrPatrizia Cavazzoni, acting director of the FDA's Center for Drug Evaluation,It was only after a rigorous assessment by our drug assessment and research center scientists that we took this action"